Hemcheck appoints Jesper Birgemo as new CEO
Jesper assumes the position on November 28, 2023. Joen Averstad continues as CFO. The decision follows the transaction with Bio Vitos.
See the latest news and media coverage for Hemcheck. We track all announcements, press releases, and industry mentions in real time, all in one place.
Point-of-care hemolysis detection tests
hemcheck.seLast updated
In short: Hemcheck transitioned into Bio Vitos Pharma AB following a major transaction with Bio Vitos and appointed Jesper Birgemo as the new CEO.
Jesper assumes the position on November 28, 2023. Joen Averstad continues as CFO. The decision follows the transaction with Bio Vitos.
The meeting approves transaction with Bio Vitos, name change to Bio Vitos Pharma AB, board changes with Richard Wall as chairman.
Revenues amounted to 103,082 SEK in Q3 and 2,176,264 SEK Jan-Sep. The deal with Bio Vitos was completed after Nasdaq's conditional approval.
The meeting is held on November 24, 2023 in Solna with proposals for name change, seat to Uppsala, new business purpose and board election.
Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data. Sign up for our newsletter to get the latest...
First North-listed Hemcheck, which develops and commercializes products for detecting hemolysis in blood samples, reports an operating result of -3.2 million kronor for the first quarter...
SOLNA, Sweden, Nov. 1, 2022 /PRNewswire/ -- Hemcheck Sweden AB has today received the certification according to the quality standard ISO 13485. The certificate has...
SOLNA, Sweden, Nov. 11, 2022 /PRNewswire/ -- Hemcheck Sweden AB has signed a distributor agreement with Levi Biotech regarding the Italian market. The agreement is...
Track Hemcheck and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.